皮埃佐1的激活加快了骨关节炎的进展和美西宁的向治疗效果
Donghao Gan1, Chu Tao1, Xiaowan Jin1
1Department of Biochemistry, School of Medicine, Guangdong Provincial Key Laboratory of Cell Microenvironment and Disease Research, Shenzhen Key Laboratory of Cell Microenvironment, Southern University of Science and Technology, Shenzhen, China.
Journal of advanced research
|September 27, 2023
概括
骨关节炎 (OA) 通过Piezo1激活而恶化. 药物艺术素 (ART) 抑制Piezo1,通过减少疾病进展,为OA提供潜在的新治疗方法.
科学领域:
- 生物医学工程 生物医学工程
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 骨关节炎 (OA) 是一种广泛的退行性关节疾病,机制不明,其中异常的机械应力是关键因素.
- 目前对OA的治疗方法有限,这凸显了针对疾病途径的新型治疗策略的需要.
研究的目的:
- 研究Piezo1通道激活在骨关节炎的发展和进展中的作用.
- 探索用于骨关节炎治疗的Piezo1向疗法的潜力.
主要方法:
- 在人类OA软骨和小鼠模型中评估Piezo1表达.
- 在小鼠中利用基因Piezo1删除和Yoda1 (Piezo1激活剂) 注射来研究OA的进展.
- 评估了阿尔特米西宁 (ART) 对Piezo1激活,状细胞代谢和OA病变的影响.
主要成果:
- 在OA软骨中,Piezo1表达升高.
- Piezo1 删除减轻了OA的发展,而激活则加剧了它.
- 鉴定出甲素 (ART) 是一种强有力的Piezo1抑制剂,可降低与OA相关的基因表达,并缓解小鼠OA病变.
结论:
- Piezo1在促进骨关节炎的发展和进展方面发挥着至关重要的作用.
- 艺术素 (ART) 显示出作为一种新型治疗性关节炎的新药的前景.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K


